|
Efavirenz use is associated with severe Vitamin D deficiency in a large, ethnically diverse urban UK HIV cohort
Presented by Tanya Welz (United Kingdom).
T. Welz1, K. Childs1, F. Ibrahim2, M. Poulton1, F. Post2
1King's College Hospital London, London, United Kingdom, 2King's College London, London, United Kingdom
Background: Several studies have shown high rates of Vitamin D insufficiency among HIV patients. Recent studies have suggested that specific antiretroviral classes may lower serum 25(OH)D [circulating vitamin D] levels. Optimal vitamin D status is associated with numerous beneficial health outcomes.
Method: Cross sectional study of 1041 adult HIV outpatients in London. Risk factors for severe Vit.D deficiency (< 10µg/L) and raised ALP were examined using logistic regression.
Results: Median age was 40 yrs (35,46), 59.4% men, 35% white, 58% black, CD4 452 cells/mm3 (324,613). Median serum 25(OH)D was 13.3 µg/L (8.2,20.8). 91.2% had 25(OH)D levels < 30 µg/L (suboptimal), 72.9% had 25(OH)D < 20 µg/L (deficient), 34.2% < 10 µg/L (severely deficient) and 6.4% had undetectable 25(OH)D levels. Factors associated with lower serum 25(OH)D were black race, season and currently being on Efavirenz (EFZ). Patients on TNF had significantly higher ALP (with normal GGT) levels than those on other HAART (p< 0.0001).
Conclusions: Hypovitaminosis D is almost universal in this cohort. EFZ use was associated with a lower 25(OH)D and TDF with higher ALP. Further studies are required to define the potential mechanisms and clinical implications of this interaction between ART, Vitamin D and bone.
[Table]
Download the e-Poster
|